And in another pan-tumor analysis, the scholars counted the prevalence of POLE/POLD variations among 47,721 cancer patients, 2.79 and 1.37%, respectively; and the TMB level in those with such mutations was obviously higher than those without mutations (84). This evidence concerns the gene POLE and neoplasm.